drugset / Trial / NCT02986100

Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib

NCT02986100

Phase 1 Completed 6 enrolled pharmaand GmbH
NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to characterize the mass balance, absorption, metabolism, and elimination pathways of orally administered \[14C\] rucaparib followed by cycle by cycle treatment with rucaparib continuing until disease progression or other reason for discontinuation

Timeline

Start
2016-11
Primary completion
2017-12
Completion
2018-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Rucaparib Small molecule 600 mg Oral

Indications